740 / 1631
IBRUTINIB IN B-CELL LYMPHOMA
Advani RH
et al. J Clin Oncol
2013;31:88‒94
Responders
(n/N)
Mantle cell
7/9
CLL/SLL
11/16
FL
6/16
DLBCL
2/7
WM
3/4
MZL
1/4
ORR
60%
N=56. Median 3 (1‒10) prior therapies
56 patients with R/R NHL, CLL, or WM who
had failed
1 previous therapy